FOR HEALTHCARE PROFESSIONALS ONLY

This website is information resource for Taiwan. It is intended for healthcare professionals only outside of Taiwan who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are not a healthcare professional in Taiwan click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

Like every person, every tumour is unique.
Our high-quality portfolio of comprehensive genomic profiling services provides powerful insights to help optimise and personalise treatment strategies for patients in diverse clinical situations.1–10

A comprehensive approach to genomic profiling

The Foundation Medicine comprehensive genomic profiling approach broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients’ treatment options.*1–5 Clinicians then receive a clear, in-depth report that supports clinical decision-making by providing insights on the patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.11

Our comprehensive genomic approach broadly analyses the tumour genome to identify clinically relevant alterations
Our portfolio of comprehensive genomic profiling services enables treatment strategies to be personalised for patients in diverse clinical situations

A high-quality portfolio of services

Our high-quality portfolio of services helps optimise and personalise treatment strategies for patients in diverse clinical situations.7–9

Overview of services

Overview Tissue-based test for solid tumours, based on our analytically and clinically validated, FDA-approved comprehensive platform† Liquid biopsy test for solid tumours when tissue biopsy is tissue for analysis and/or disease progression is suspected For haematological malignancies and sarcomas personalised treatment decisions 7,10,12 Opens up the opportunity of comprehensive genomic profiling with a single blood draw 8,13 For diagnostic, prognostic and predictive insights to support treatment 9 FFPE Peripheral whole blood FFPE, peripheral whole blood, bone marrow aspirate Sample type 324 70 >400 Genes Tumour mutational burden (TMB) Microsatellite instability (MSI) EXPLORE EXPLORE EXPLORE

Combined commitment

As part of our long-standing commitment to pioneering progress in precision medicine, molecular insights leader Foundation Medicine has become a member of the Roche Group. Together Roche and Foundation Medicine are bringing comprehensive genomic profiling to cancer patients around the world, combining Roche’s expertise and commitment in oncology and Foundation Medicine’s leading technology, validation and experience in cancer profiling.14
Oncology Molecular insights Precision medicine

*Comprehensive genomic profiling is a tumour testing method that utilises next generation sequencing technology to identify all four classes of alterations across a large set of cancer-related genes (>50) known to drive cancer across tumour types. Comprehensive genomic profiling is a ‘pan-tumour’ approach, or applicable for use across any type of cancer.

†Clinical validation based on demonstrated concordance with the following companion diagnostics: cobas® EGFR Mutation Test, Ventana ALK (D5F3) CDx Assay, Vysis ALK Break-Apart FISH Probe Kit, therascreen® KRAS RGQ PCR Kit, Dako HER2 FISH PharmDx® Kit, cobas® BRAF V600 Mutation Test, THxID® BRAF kit. For more information, please see the FoundationOne®CDx Technical Specifications available at: www.rochefoundationmedicine.com/f1cdxtech.

FDA, US Food and Drug Administration. FFPE, formalin-fixed paraffin-embedded.

本平台原非用於通報不良事件(副作用),但您可透過網站,向台灣羅氏藥品安全部門通報不良事件,或前往全國藥物不良反應系統網站進行通報。    

 

References
  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  3. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  4. Ross JS et al. Cancer 2016; 122: 2654–2662.
  5. Suh JH et al. Oncologist 2016; 21: 684–691.
  6. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  7. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed March 2019).
  8. FoundationOne®Liquid Technical Specifications, 2018. Available at: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (Accessed March 2019).
  9. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
  10. FoundationOne®CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed March 2019).
  11. FoundationOne®CDx Sample Report, 2018. Available at: www.rochefoundationmedicine.com/reporting (Accessed March 2019).
  12. FoundationOne®CDx FDA Approval Press Release, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.htm (Accessed March 2019).
  13. Clark TA et al. J Mol Diagn 2018; 20: 686–702.
  14. Roche Media Release, 2018. Available at: https://www.roche.com/media/releases/med-cor-2018-06-19.htm (Accessed March 2019).